Biodesix Inc. (BDSX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Biodesix, Inc. (BDSX) Reports Q4 Loss, Beats Revenue Estimates
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $1.2 per share a year ago.
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 325.67%: Here's is How to Trade
The mean of analysts' price targets for Biodesix (BDSX) points to a 325.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biodesix, Inc. (BDSX) Reports Q3 Loss, Tops Revenue Estimates
Biodesix, Inc. (BDSX) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.6. This compares to a loss of $1.4 per share a year ago.
Biodesix, Inc. (BDSX) Q3 2025 Earnings Call Transcript
Biodesix, Inc. ( BDSX ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Scott Hutton - President, CEO & Director Robin Cowie - CFO, Secretary & Treasurer Conference Call Participants Christopher Brinzey - Westwicke Partners, LLC Margarate Boeye - William Blair & Company L.L.C., Research Division Alexander Vukasin - Canaccord Genuity Corp., Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division William Ruby - TD Cowen, Research Division Presentation Operator " Christopher Brinzey Westwicke Partners, LLC " Scott Hutton President, CEO & Director " Robin Cowie CFO, Secretary & Treasurer " Margarate Boeye William Blair & Company L.L.C.
Biodesix, Inc. (BDSX) Q2 2025 Earnings Call Transcript
Biodesix, Inc. (NASDAQ:BDSX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Robin Harper Cowie - CFO, Secretary & Treasurer Scott Hutton - President, CEO & Director Conference Call Participants Alexander Davis Vukasin - Canaccord Genuity Corp., Research Division Andrew Frederick Brackmann - William Blair & Company L.L.C., Research Division Thomas Flaten - Lake Street Capital Markets, LLC, Research Division William Ruby - TD Cowen, Research Division William Bishop Bonello - Craig-Hallum Capital Group LLC, Research Division Christopher F.
Biodesix, Inc. (BDSX) Reports Q2 Loss, Tops Revenue Estimates
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.08 per share a year ago.
Biodesix, Inc. (BDSX) Q1 2025 Earnings Call Transcript
Biodesix, Inc. (NASDAQ:BDSX ) Q1 2025 Results Conference Call May 13, 2025 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Andrew Brackmann - William Blair Sung Ji Nam - Scotiabank Kyle Mikson - Canaccord Genuity Thomas Flaten - Lake Street Capital Markets Bill Bonello - Craig-Hallum Operator Good day and thank you for standing by. Welcome to the Biodesix's Q1 2025 Earnings Conference Call.
Biodesix, Inc. (BDSX) Reports Q1 Loss, Misses Revenue Estimates
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago.
Biodesix (BDSX) Upgraded to Buy: What Does It Mean for the Stock?
Biodesix (BDSX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biodesix, Inc. (BDSX) Q4 2024 Earnings Call Transcript
Biodesix, Inc. (NASDAQ:BDSX ) Q4 2024 Earnings Conference Call March 3, 2025 4:30 PM ET Company Participants Chris Brinzey - Investor Relations Scott Hutton - Chief Executive Officer Robin Harper Cowie - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Kyle Mikson - Canaccord Dan Brennan - TD Cowen Thomas Flaten - Lake Street Capital Markets William Bonello - Craig-Hallum Sung Ji Nam - Scotiabank Operator Good day and thank you for standing by. Welcome to the Biodesix's Q4 2024 Earnings Conference Call.
BDSX Stock Rises After Publication of Study Data for Nodify CDT Test
Biodesix announces positive study data for its Nodify CDT blood-based lung nodule test published in CHEST Pulmonary Journal.
Biodesix (BDSX) Loses -22.98% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Biodesix (BDSX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
